Chronic Hypoxia and Tubulointerstitial Injury: A Final Common Pathway to End-Stage Renal Failure
Masaomi Nangaku
Division of Nephrology and Endocrinology, University of Tokyo School of Medicine, Tokyo, Japan
Address correspondence to: Dr. Masaomi Nangaku, Division of Nephrology and Endocrinology, University of Tokyo School of Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. Phone: 81-3-5800-8648; Fax: 81-3-5800-8806; E-mail: mnangaku-tky{at}umin.ac.jp
Recent studies emphasize the role of chronic hypoxia in thetubulointerstitium as a final common pathway to end-stage renalfailure. When advanced, tubulointerstitial damage is associatedwith the loss of peritubular capillaries. Associated interstitialfibrosis impairs oxygen diffusion and supply to tubular andinterstitial cells. Hypoxia of tubular cells leads to apoptosisor epithelial-mesenchymal transdifferentiation. This in turnexacerbates fibrosis of the kidney and subsequent chronic hypoxia,setting in train a vicious cycle whose end point is ESRD. Anumber of mechanisms that induce tubulointerstitial hypoxiaat an early stage have been identified. Glomerular injury andvasoconstriction of efferent arterioles as a result of imbalancesin vasoactive substances decrease postglomerular peritubularcapillary blood flow. Angiotensin II not only constricts efferentarterioles but, via its induction of oxidative stress, alsohampers the efficient utilization of oxygen in tubular cells.Relative hypoxia in the kidney also results from increased metabolicdemand in tubular cells. Furthermore, renal anemia hinders oxygendelivery. These factors can affect the kidney before the appearanceof significant pathologic changes in the vasculature and predisposethe kidney to tubulointerstitial injury. Therapeutic approachesthat target the chronic hypoxia should prove effective againsta broad range of renal diseases. Current modalities includethe improvement of anemia with erythropoietin, the preservationof peritubular capillary blood flow by blockade of the renin-angiotensinsystem, and the use of antioxidants. Recent studies have elucidatedthe mechanism of hypoxia-induced transcription, namely thatprolyl hydroxylase regulates hypoxia-inducible factor. Thishas given hope for the development of novel therapeutic approachesagainst this final common pathway.
Once renal damage reaches a certain threshold, the progressionof renal disease is consistent, irreversible, and largely independentof the initial insult. The final common pathway in this processhas been studied closely. The hyperfiltration theory of Brenneret al. (1), which suggests that the progression of renal diseaseresults from glomerular hemodynamic changes, has emerged asa popular concept. However, close pathologic analysis showsthat functional impairment of the kidney is better correlatedwith the degree of tubulointerstitial damage than with thatof glomerular injury (25), and this finding in turn hasled to the broad recognition that the final common pathway ofkidney failure operates principally in the tubulointerstitium(68).
The tubulointerstitial damage induced by the final common pathwayleads to a decrease in GFR via several mechanisms. Tubular atrophyincreases fluid delivery to the macula densa and triggers adecrease in GFR via tubuloglomerular feedback. Tubular damagealso leads to the development of atubular glomeruli and decreasesthe number of functional nephrons. Finally, tubulointerstitialfibrosis impairs blood flow in the corresponding region andinduces ischemic injury of nephrons.
One common mechanism that leads to renal failure via tubulointerstitialinjury is massive proteinuria (9,10). Large-scale prospectivestudies, including the Modification of Diet in Renal Diseaseand Ramipril Efficacy in Nephropathy, have established the relationshipbetween proteinuria and progressive renal disease (11,12). Systematicanalyses of these reveal that greater urinary protein excretionpredicts a faster decline in GFR (13,14). Accumulating evidencesuggests that filtered macromolecules exert a number of criticaleffects on tubular cells, including the more general effectsof lysosomal rupture and energy depletion, as well as more particulareffects involving direct tubular injury by specific substancessuch as complement components (15,16).
In some diseases, however, including hypertensive nephrosclerosis,tubulointerstitial injury progresses to end-stage kidney failurein the absence of massive proteinuria. Furthermore, analysisof previous clinical studies shows that decreasing systemicBP and proteinuria only partially explain the beneficial effectsof blockade of the renin-angiotensin system (RAS) on reducingthe risk for progression of kidney disease (17,18). It thusis crucial to identify an alternative or additional mechanismand,hopefully, a more unifying onethat is common to manyforms of glomerular disease.
Chronic Hypoxia at the Center of Tubulointerstitial Injury and ESRD
In the kidney, most afferent glomerular arterioles arise fromthe interlobular arteries. The afferent arterioles divide dichotomouslyand gives rise to glomerular capillaries, which merge togetheragain at the vascular pole to form the efferent arterioles.Efferent arterioles enter the peritubular capillary plexus,which surrounds tubules and offers oxygen and nutrients to tubularand interstitial cells (Figure 1).
Figure 1. The microvasculature of the nephron. The peritubular capillary plexus is fed by glomerular efferent arterioles and supplies nutrients and oxygen to tubular and interstitial cells. Illustration by Josh GramlingGramling Medical Illustrations.
Although blood flow to the kidney is high, accounting for 20%of cardiac output, the presence of oxygen shunt diffusion betweenarterial and venous vessels that run in close parallel contactmeans that renal tissue oxygen tensions are in fact comparativelylow (19,20). Oxygen tension in the renal medulla, for example,does not rise above 10 mmHg. That in the renal cortex is morevariable, however, with an average pO2 of approximately 30 mmHg,but decreases dramatically in accordance with changes in renalperfusion. As a consequence, the kidney is somewhat sensitiveto changes in oxygen delivery. Although this sensitivity hasthe merit of facilitating the kidneys in their adjustment oferythropoietin (EPO) production to changes in oxygen supply,it also renders them prone to hypoxic injury.
The chronic hypoxia hypothesis, proposed by Fine et al. (21),emphasizes chronic ischemic damage in the tubulointerstitiumas a final common pathway in end-stage kidney injury. Sinceits introduction, this fascinating hypothesis has been investigatedintensively and subsequently validated by Eckardt, Johnson,and many other investigators (2224).
Loss of Peritubular Capillaries and Fibrosis in Chronic Renal Disease
Chronic ischemia in the tubulointerstitium occurs via severalmechanisms acting in concert. Histologic studies of human kidneysand animal models have shown that extensive tubulointerstitialinjury is associated with damage to renal arterioles and arteriesas well as with distortion and loss of peritubular capillaries(2529). It therefore is of little wonder that fibrotickidneys with advanced renal disease are devoid of peritubularcapillary blood supply and oxygenation to the correspondingregion (Figure 2A).
Figure 2. Multiple mechanisms of chronic hypoxia in the kidney. Mechanisms of hypoxia in the kidney of chronic kidney disease include loss of peritubular capillaries (A), decreased oxygen diffusion from peritubular capillaries to tubular and interstitial cells as a result of fibrosis of the kidney (B), stagnation of peritubular capillary blood flow induced by sclerosis of "parent" glomeruli (C), decreased peritubular capillary blood flow as a result of imbalance of vasoactive substances (D), inappropriate energy usage as a result of uncoupling of mitochondrial respiration induced by oxidative stress (E), increased metabolic demands of tubular cells (F), and decreased oxygen delivery as a result of anemia (G). Illustration by Josh GramlingGramling Medical Illustrations.
Even when the peritubular capillaries are essentially intact,however, interstitial fibrosis still impairs tubular oxygensupply. This is because the extended distance between the capillariesand tubular cells reduces the efficiency of oxygen diffusion(Figure 2B). In this regard, it is notable that hypoxia perse is a profibrogenic stimulus for tubular cells, interstitialfibroblasts, and renal microvascular endothelial cells. Tubularcells under hypoxic conditions undergo epithelial-mesenchymaltransdifferentiation to become myofibroblasts (30). Hypoxiacan also activate fibroblasts and change the extracellular matrixmetabolism of resident renal cells (31,32). A fibrogenic responseleads in turn to the obliteration of peritubular capillaries.Furthermore, renal tubular cells that are subjected to severeor prolonged hypoxia develop in their mitochondria functionaldeficits that lead to persistent energy deficits, subsequentlycausing them to undergo apoptosis (33). Together, chronic hypoxiain this compartment can lead to transdifferentiation or apoptosis(or both) of tubular cells, activation of resident fibroblasts,and further obliteration and loss of peritubular capillarieswith progression of fibrosis. These changes may combine to institutea vicious cycle of regional hypoxia and progressive kidney failurein the late stages of disease.
Glomerular Damage and Hypoxia of the Tubulointerstitium
Hypoxia also plays a pathogenic role in the relatively earlystages of kidney disease, well before the development of structuraltubulointerstitial injury. Peritubular capillaries occur downstreamof the glomerular efferent arterioles. Impairment of the "parent"glomerular capillary bed, as occurs in glomerulosclerosis, forexample, thus automatically results in a decrease in peritubularperfusion and tubular oxygen supply (Figure 2C). In a modelof accelerated glomerulosclerosis induced by repeated injectionof anti-Thy1 antibody in uninephrectomized rats, we observeda decrease in blood flow in peritubular capillaries using intravitalmicroscopy and physiologic lectin perfusion (34). Stagnationof peritubular capillary blood flow was associated with hypoxiain the corresponding tubulointerstitium, and both preceded thedevelopment of histologic tubulointerstitial injury and peritubularcapillary loss.
Hemodynamic Maladjustment in the Tubulointerstitium: Imbalance of Vasoactive Substances
Even in the presence of structurally intact glomeruli, imbalancesin vasoactive substances and associated intrarenal vasoconstrictioncan cause chronic hypoxia in the kidney in the early stage ofkidney disease, before the development of histologic changesin the tubulointerstitium (Figure 2D). Futrakul et al. (35)performed intrarenal hemodynamic studies in patients with severeglomerulonephritis using radioisotope techniques and showedthat elevated efferent arteriolar resistance and decreased peritubularcapillary flow were associated with reversible renal functionalimpairment. This reversible change in peritubular capillaryflow may have reflected an improvement in the imbalance of vasoactivesubstances in the kidney. They recently extended these observationsto report a correlation between a decrease in peritubular capillaryflow and tubular dysfunction in patients with type 2 diabetesand normoalbuminuria (36). These results support the conceptthat chronic hypoxia may/can induce tubulointerstitial injury,which eventually leads to ESRD in patients with a variety ofkidney diseases.
Among various vasoactive substances, local activation of RASis especially important because it can lead to constrictionof efferent arterioles, hypoperfusion of postglomerular peritubularcapillaries, and subsequent hypoxia of the tubulointerstitiumin the downstream compartment. To clarify the mechanism of theseeffects, we used a remnant kidney model in rats induced by ligationof renal artery branches, in which RAS is markedly activated.Our computer-assisted morphologic analysis demonstrated narrowingand distortion of peritubular capillaries with decreased bloodflow and hypoxia in a very early phase in this model, beforethe development of structural kidney damage (37). In addition,angiotensin II damages endothelial cells directly: Administrationof angiotensin II to rats causes the loss of peritubular capillaries,an effect that is ameliorated by receptor blockade (38,39).A second important mechanism of angiotensin IIinducedischemia is inefficient cellular respiration and hypoxia viaoxidative stress, which is detailed below. Thus, angiotensinII induces tubulointerstitial hypoxia via both hemodynamic andnonhemodynamic mechanisms. Intrarenal vasoconstriction may alsooccur secondary to increased local endothelin or a local lossof vasodilating nitric oxide (NO).
Role of Anemia in Hypoxia of the Kidney
The amount of O2 delivered, either to the whole body or to specificorgans, is the product of blood flow and arterial O2 content.Under most circumstances, oxygen delivery (DO2) is determinedusing the equation DO2 = CO x (%Sat x 1.39 x [Hb]), where COis cardiac output in liters per minute, %Sat is percentage ofhemoglobin O2 saturation, [Hb] is hemoglobin concentration ingrams per liter, and 1.39 is the hemoglobin binding constant.From the equation, anemia in kidney disease may accelerate thedecline in renal function by inducing tubulointerstitial hypoxia(Figure 2G). The important role of anemia is emphasized by thefact that anemia is observed at a relatively early stage ofrenal dysfunction. Both the Third National Health and NutritionExamination Survey and the National Kidney Foundation KidneyEarly Evaluation Program showed that the risk for anemia significantlyincreases when GFR falls below 60 ml/min per 1.73 m2 (40,41).Studies that have confirmed anemia as an independent risk factorfor ESRD include a retrospective multivariate logistic analysisof 71,802 subjects that was performed by Iseki et al. (42) andan analysis of the data of the Reduction of Endpoints in NIDDMwith the Angiotensin II Antagonist Losartan study of patientswith type 2 diabetic nephropathy (43). The average increasein adjusted relative risk in the latter study was 11% for each1-g/dl decrease in hemoglobin concentration.
Oxidative Stress and Inefficient Cellular Respiration
Chronic kidney disease is associated with oxidative stress.Angiotensin II, which is often upregulated in renal diseases,also promotes renal oxidative stress by stimulating NADPH oxidase.Furthermore, renal anemia contributes to oxidative stress aserythrocytes represent a major antioxidant component of theblood.
Superoxide leads to decreased NO bioavailability through ONOOformation. Adler et al. (44) showed that, because NO is a suppressorof mitochondrial respiration, depletion of NO by oxidative stressmay stimulate mitochondrial respiration and uncouple it fromchemical energy consumption, resulting in tissue hypoxia (Figure 2E).
Kidneys of the spontaneously hypertensive rat (SHR), which characteristicallyundergo oxidative stress, revealed enhanced oxygen usage relativeto tubular sodium transport and lower intrarenal pO2 (45). Ameliorationof oxidative stress improved renal oxygenation in a model ofdiabetic nephropathy (46) and in the angiotensin II continuousinfusion model (47). The same oxidative stressrelatedmechanism may cause tubulointerstitial hypoxia in the agingkidney (48). It is likely that the renal hypoxia in these modelsresults from a decrease in NO bioavailability and subsequentuncoupling of mitochondrial respiration as a result of oxidativestress.
Relative Hypoxia as a Result of Increased Metabolic Demand
When metabolic demand is increased, cells may suffer from relativehypoxia even under the maintenance of otherwise normal bloodflow. Studies that have used the blood oxygen leveldependent(BOLD)magnetic resonance imaging (MRI) technique (seeDetection of Hypoxia in the Kidney section) have demonstratedthat streptozotocin-induced diabetic kidneys suffer from tissuehypoxia at an early stage, before the development of structuralchanges (49). A possible explanation is that the hyperfiltrationthat occurs early in diabetic nephropathy leads to the increaseddelivery of sodium to tubular cells, imposing an excessive tubularsodium reabsorption workload relative to oxygen supply and subsequentlyresulting in tubular hypoxia (Figure 2F). Whether proteinuriacauses functional hypoxia as a result of increased metabolicdemand for reabsorption is an important question for futurestudy.
Despite an ever-increasing need for methods to identify andquantify hypoxic cells in vivo, suitable tools for detectinglow oxygenation within tissues remain in short supply. Amongthose with potential diagnostic and research use are chemicaltools such as pimonidazole, which is reduced under conditionsof low oxygen availability. Visualization of this reaction allowsus to detect hypoxic cells. These chemical methods are subjectto a number of limitations, however: Their sensitivity is relativelylow, detecting hypoxic cells at oxygen levels of <10 mmHgonly, and they are not quantitative. Moreover, the hypoxia probeis metabolized and bound to cells over a 1- to 3-h period, requiringthe assumption that oxygen content as well as delivery of thechemical compound, in terms of blood flow to the tissue, remainconstant over the observation period. An additional limitationis that ischemia might impair the delivery of the compound tohypoxic tissues.
Polarographic oxygen sensors serve as true oxygen monitors,but the method is invasive and functional in only a limitedrange of tissues. In addition, because their signal is proportionalto the measured quantity, they can become noisy and inaccurate,especially at low oxygen levels over relatively large tissuevolumes.
To overcome these problems, Tanaka from our group recently establisheda novel transgenic rat (50). These animals, which were highlightedin a recent issue of the JASN (51), express luciferase taggedwith FLAG under a promoter composed of a tandem repeat of hypoxia-induciblefactor (HIF) binding sites, providing a wide dynamic detectionrange of quantitative oxygen concentration with resolution downto the individual cell level. These animals enabled us to demonstratedifferent patterns of hypoxia at the early stage in variouskidney disease models. An impressive regional correlation wasnoted between areas of hypoxia and areas of macrophage accumulation,apoptosis, and cell proliferation.
With regard to future clinical applications, BOLD-MRI is a promisingtool for the estimation of tissue oxygenation in vivo. Whereasoxyhemoglobin is diamagnetic, deoxyhemoglobin is paramagnetic.Thus, when red blood cells that contain deoxyhemoglobin areplaced in the magnetic field of an MRI, they cause field distortion,which appears as BOLD contrast in the resulting images. Limitationsat this time include difficulty in obtaining reproducible andreliable information in this mobile organ, i.e., the kidney.
Because chronic hypoxia in the tubulointerstitium is a finalcommon pathway to ESRD, therapeutic approaches that target thechronic hypoxia should prove effective against a broad rangeof renal diseases. Potential treatment modalities that targetchronic hypoxia in the kidney are summarized in Table 1. Detailsof each are discussed in the following sections.
Table 1. Treatment modalities that target chronic hypoxia in the kidneya
Treatment Targeting Hypoxic Tubulointerstitial Damage: EPO
Because anemia is a risk factor for renal failure, correctionof anemia by EPO and the subsequent improvement in oxygen deliveryto the kidney may delay the progression of renal failure. Thisexpectation was supported by several studies that suggestedthat progression might be delayed by an improvement in anemiaby treatment with EPO. Gouva et al. (52) recently conducteda randomized, controlled trial of early versus deferred initiationof EPO in nondiabetic predialysis patients. The early treatmentarm was started immediately on EPO titrated to produce a targethemoglobin level of >13 g/dl, whereas the deferred treatmentarm started EPO only when hemoglobin decreased below 9 g/dl.The results clearly showed that early initiation of EPO in predialysispatients with anemia significantly slows the progression ofrenal disease. However, some other trials, including the muchlarger Cardiovascular Risk Reduction by Early Anemia Treatmentwith Epoetin trial, could not confirm beneficial effects ofintensive treatment with EPO, and renoprotective effects ofEPO requires further investigation.
Blockade of RAS to Ameliorate Tubulointerstitial Hypoxia
Norman et al. (53) were the first to show that blockade of RASpreserved peritubular capillary perfusion and tissue oxygenationin healthy anesthetized rats. In a remnant kidney model, wedemonstrated that treatment with the angiotensin receptor blockerolmesartan restored blood flow in peritubular capillaries andimproved oxygenation of the kidney (37). Although these improvementsin kidney oxygenation by RAS inhibition are multifactorial,one important mechanism is the dilation of efferent glomerulararterioles and consequent increase in blood supply to the downstreamtubulointerstitium. Inhibitors of RAS also serve as antioxidantsand should ameliorate uncoupling of mitochondrial respiration,leading to more efficient use of oxygen. Supporting the lattermechanism, administration of an angiotensin receptor blockercorrected the reduced pO2 in the cortices of the SHR and reversedthe inefficient use of O2 for Na+ transport (54).
Protection of the Tubulointerstitial Vasculature
Protection of the tubulointerstitial vasculature theoreticallyshould preserve blood supply and guarantee oxygenation to thecorresponding compartment. Physiologically, endothelial cellsare covered with a layer of heparan sulfate proteoglycans, whichare crucial to the anticoagulant and anti-inflammatory propertiesof the endothelium. Endothelial cell injury is associated withthe loss of these proteoglycans on the cell surface and thrombusformation, followed by subsequent ischemic tubulointerstitialdamage. On this basis, we hypothesized that administration ofdextran sulfate may protect the kidney from endothelial damageby re-establishing the intact endothelial surface. To investigatethis, we used a model of thrombotic microangiopathy inducedby renal artery perfusion of an antiglomerular endothelial antibody.Results showed that the administration of dextran sulfate protectedthe kidney against endothelial damage, probably by acting asa "repair coat" (55) to re-establish the intact anticoagulantand anti-inflammatory surface of the injured endothelium.
Kang et al. (56) treated rats with remnant kidneys with vascularendothelial growth factor (VEGF). This treatment improved renalfunction and lowered mortality rates compared with the vehiclecontrol, and histology confirmed an increase in peritubularcapillary endothelial cell proliferation and a decrease in peritubularcapillary rarefaction. These results showed that treatment withVEGF protected the kidney by both the preservation of the capillaryendothelium and the partial reversal of the impaired angiogenesis.
HIF as a Target for Drug Development
Although VEGF is a promising therapeutic modality, a potentialpitfall of the induction of vessels by overexpression of a singlegene such as VEGF is that the resulting vessels may be leaky,immature, or irregular. This is because the formation of a functionallyintact microvasculature requires the coordinated activationof various genes. Rather, a more promising approach to protectingtissues against hypoxia is the activation of a "master gene"switch that results in a broad and coordinated downstream reaction.
At the center of the cellular response to hypoxia is HIF (57,58).HIF is composed of two subunits, an oxygen-sensitive HIF- subunitand a constitutively expressed HIF- subunit (also known as arylhydrocarbon receptor nuclear translocator [ARNT]). The firstisoform of HIF-, HIF-1, was originally identified and clonedas a high-affinity DNA binding protein localized to the 3' hypoxia-responsiveelement of the EPO gene (59,60). Both HIF-1 and HIF-1 are membersof the basic helix-loop-helix PER/ARNT/SIM (HLH-PAS) familyof transcription factors. HIF binds to the hypoxia-responsiveelement in the cis-regulatory regions of its target genes andtranscriptionally activates various genes encoding proteinsthat mediate adaptive responses to reduced oxygen availability.
Under normoxic conditions, two conserved proline residues withinthe central oxygen-dependent degradation domains of the HIFproteins are hydroxylated by the protein products prolyl hydroxylasedomain containing (PHD) (61). This promotes binding of the vonHippel Lindau tumor suppressor protein, part of a ubiquitinligase complex, resulting in polyubiquitylation and rapid degradation.Similarly, a conserved asparagine residue in the carboxyl-terminaltransactivation domain of the HIF proteins is hydroxylated innormoxia by factor inhibiting HIF (FIH), preventing recruitmentof the p300/CREB-binding protein transcriptional co-activatorsand thus leading to transcriptional repression. Under hypoxia,oxygen is lacking as an essential substrate for the hydroxylationreaction, and the unmodified HIF proteins avoid degradationbut rather heterodimerize with HIF- and upregulate the transcriptionof target genes. The biologic significance of HIF in the kidneyunder physiologic and pathologic conditions was demonstratedrecently by Manotham from our group, who used in vivo gene transferof DNA expressing negative dominant HIF and constitutively activefusion protein of HIF (62).
Owing to its ability to induce the expression of a variety ofoxygen-regulated and renoprotective genes in a coordinated andphysiologic manner, stimulation of HIF-1 signaling may be moreeffective in ischemic states. For emphasizing the efficacy ofthis "master gene" switch, transgenic mice expressing constitutivelyactive HIF-1 in the epidermis displayed an increase in dermalcapillaries with a 13-fold elevation of VEGF (63). Despite amarked induction of hypervascularity, HIF-1 did not induce edema,inflammation, or vascular leakage, phenotypes that develop intransgenic mice that overexpress VEGF in skin.
A recently discovered isoform of HIF-1, HIF-2, has been shownto possess both structural and functional similarity to HIF-1.HIF-1 and HIF-1 are expressed in most cell types, whereas HIF-2shows a more restricted pattern of expression (57,64). To studythe expression of HIF-1 and HIF-2 in the kidney, Eckardtsgroup used high-amplification immunohistochemical analyses (65,66)and showed that HIF-2 was induced by hypoxia in peritubularendothelial cells and fibroblasts as well as glomerular endothelialcells, whereas HIF-1 was localized predominantly in the tubularcells (65). These results are consistent with those of studiesthat have used a surrogate marker for HIF-2 in genetically engineeredmice (67). In these mice, disruption of the murine HIF-2a genewas accomplished by homologous recombination in embryonic stemcells using a targeting plasmid in which a modified form of-galactosidase (-gal) was substituted for exon 2 of the HIF-2gene. Activity staining for nuclear-localized -gal revealedstrong expression predominantly in vascular endothelial cellsbut also in the renal interstitial cell compartment, whereas-gal staining was not evident in renal tubular cells.
Upregulation of the two HIF- isoforms in the kidney by hypoxiawas demonstrated in models of segmental renal infarction andradiocontrast nephropathy (68,69). Although cell-type specificityof HIF isoforms in these models was consistent with previousfindings, temporal and spatial profiles of HIF activation wererelatively complex, suggesting an important but complicatedrole of HIF in tissue preservation as a response to regionalrenal hypoxia. Our recent in vitro experiments showed that HIF-1in tubular epithelial cells promotes proliferation of endothelialcells and that HIF-2 that is overexpressed in renal endothelialcells mediates migration and network formation; these resultssuggest a specific role of each isoform in certain cell types(70), although a clear differentiation of their roles independentof localization remains controversial.
Prolyl Hydroxylase
Three HIF prolyl hydroxylases with the potential to catalyzethis reaction have been identified, and these proteins, termedPHD1, PHD2, and PHD3, seem to have arisen by gene duplication.The contribution of each to the physiologic regulation of HIFremains uncertain. These respective isoforms each have uniquebut overlapping patterns of tissue expression. Recent experimentsusing suppression by small interference RNA showed that eachcontributes in a nonredundant manner to the regulation of bothHIF-1 and HIF-2 subunits and that the contribution of each PHDis strongly dependent on the abundance of the enzyme (71). Inmost cells, PHD2 has the most dominant effect because it issubstantially the most abundant. Whereas both PHD2 and PHD3proteins are induced by hypoxia, induction of PHD3 is particularlystriking in certain cells, and under these conditions, the contributionof PHD3 is greater than that of PHD2. PHD3 seems to contributemore substantially to the regulation of HIF-2.
Prolyl hydroxylase inhibitors have been the focus of recentstudies on novel strategies to stabilize HIF. More than halfa century ago, oral administration of cobaltous chloride wasused to treat anemia associated with chronic renal disease (72).Cobalt therapy led to a significant erythropoietic responsein association with improved appetite and greater tolerancefor medications that are necessary to correct electrolyte abnormalities.However, blood values promptly declined to pretreatment levelswhen cobalt therapy was discontinued. Although the mechanismof erythropoiesis was unknown at that time, cobalt is now recognizedas an inhibitor of PHD and thereby serves as a stimulator ofHIF. We demonstrated the renoprotective effects of chemicalpreconditioning with cobaltous chloride in an ischemic modelof renal injury (73). Administration induced upregulation ofHIF-regulated genes, such as VEGF and EPO, and subsequentlyprotected the kidney against the tubulointerstitial damage inducedby hypoxia. Cobalt treatment was also effective when given afterthe initial insult in a chronic progressive glomerulonephritismodel, a model of cyclosporin nephrotoxicity, and a model ofchronic renal failure with glomerular hypertension, demonstratingnot only its preventive but also its therapeutic potential (70,74,75).
Although cobalt administration has been somewhat effective inexperimental animals, long-term administration to humans ishindered by various side effects. Less toxic and more potentPHD inhibitors have been sought, and a variety of new candidatesare now under development (76). Whereas the mammalian genomeencodes three closely related proteins with HIF prolyl hydroxylaseactivity, only a single HIF asparaginyl hydroxylase, FIH, hasbeen identified to date. A therapeutic potential of FIH inhibitorsis also an interesting subject to be pursued.
Chronic hypoxia is the final common pathway to end-stage renalfailure. Ischemia of the kidney is induced by the loss of peritubularcapillaries in the tubulointerstitium in the late stage of renaldisease. Accumulating evidence also suggests a crucial rolefor hypoxia in the tubulointerstitium before structural microvasculaturedamage in the corresponding region, emphasizing the pathogenicrole of this condition from an early stage of kidney disease.Given this background, therapeutic approaches against this finalcommon pathway should be effective in a broad range of renaldiseases. Presently, administration of EPO to correct anemiaand blockade of RAS to preserve peritubular capillary flow andreduce oxidative stress are key to the improvement of kidneyoxygenation. In the future, the HIF transcription factor atthe center of many cellular hypoxic response pathways will bean attractive target for therapeutic manipulation.
Acknowledgments
I acknowledge Grants-in-Aid for Scientific Research from theJapan Society for the Promotion of Science (17390246).
I am grateful to Drs. William G. Couser (University of Washington,Seattle, WA), Stuart J. Shankland (University of Washington,Seattle, WA), Richard J. Johnson (University of Florida, Gainesville,FL), Juergen Floege (University of Aachen, Aachen, Germany),Kai-Uwe Eckardt (University Erlangen-Nuremberg, Germany), ReikoInagi (University of Tokyo, Tokyo, Japan), Toshio Miyata (TokaiUniversity of Tokai, Tokai, Japan), and Toshiro Fujita (Universityof Tokyo, Tokyo, Japan) for continuous support. Particular thanksare due to my friends and colleagues in my laboratory, especiallyTetsuhiro Tanaka, who has made an enormous contribution.
Footnotes
Published online ahead of print. Publication date availableat www.jasn.org.
Brenner BM, Meyer TW, Hostetter TH: Dietary protein intake and the progressive nature of kidney disease: The role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease.
N Engl J Med307
:652
659,1982[Medline]
Risdon RA, Sloper JC, de Wardener HE: Relationship between renal function and histological changes found in renal biopsy specimens from patients with persistent glomerular nephritis.
Lancet2
:363
366,1968[Medline]
Schainuck LI, Striker GE, Cutler RE, Benditt EP: Structural-functional correlations in renal disease. II. The correlations.
Hum Pathol1
:631
641,1970[Medline]
Striker GE, Schainuck LI, Cutler RE, Benditt EP: Structural-functional correlations in renal disease. I. A method for assaying and classifying histopathologic changes in renal disease.
Hum Pathol1
:615
630,1970[Medline]
Mackensen-Haen S, Bader R, Grund KE, Bohle A: Correlations between renal cortical interstitial fibrosis, atrophy of proximal tubules and impairment of glomerular filtration rate.
Clin Nephrol15
:167
171,1981[Medline]
Nangaku M: Mechanisms of tubulointerstitial injury in the kidney: Final common pathways to end-stage renal failure.
Intern Med43
:9
17,2004[CrossRef][Medline]
Eddy AA: Experimental insights into the tubulointerstitial disease accompanying primary glomerular lesions.
J Am Soc Nephrol5
:1273
1287,1994[Abstract]
Nath KA: Tubulointerstitial changes as a major determinant in the progression of renal damage.
Am J Kidney Dis20
:1
17,1992[Medline]
Remuzzi G, Bertani T: Pathophysiology of progressive nephropathies.
N Engl J Med39
:1448
1456,1998
Zoja C, Benigni A, Remuzzi G: Cellular responses to protein overload: Key event in renal disease progression.
Curr Opin Nephrol Hypertens13
:31
37,2004[Medline]
Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G: Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy.
Lancet352
:1252
1256,1998[CrossRef][Medline]
Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G: The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group.
N Engl J Med330
:877
884,1994[Abstract/Free Full Text]
Ruggenenti P, Perna A, Mosconi L, Pisoni R, Remuzzi G: Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN).
Kidney Int53
:1209
1216,1998[CrossRef][Medline]
Hunsicker LG, Adler S, Caggiula A, England BK, Greene T, Kusek JW, Rogers NL, Teschan PE: Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study.
Kidney Int51
:1908
1919,1997[Medline]
Nangaku M, Pippin J, Couser WG: Complement membrane attack complex (C5b-9) mediates interstitial disease in experimental nephrotic syndrome.
J Am Soc Nephrol10
:2323
2331,1999[Abstract/Free Full Text]
Nangaku M, Pippin J, Couser WG: C6 mediates chronic progression of tubulointerstitial damage in rats with remnant kidneys.
J Am Soc Nephrol13
:928
936,2002[Abstract/Free Full Text]
Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, de Zeeuw D, Shahinfar S, Toto R, Levey AS; AIPRD Study Group: Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: A patient-level meta-analysis.
Ann Intern Med139
:244
252,2003[Abstract/Free Full Text]
Atkins RC, Briganti EM, Lewis JB, Hunsicker LG, Braden G, Champion de Crespigny PJ, DeFerrari G, Drury P, Locatelli F, Wiegmann TB, Lewis EJ: Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy.
Am J Kidney Dis45
:281
287,2005[CrossRef][Medline]
Brezis M, Rosen S, Silva P, Epstein FH: Renal ischemia: A new perspective.
Kidney Int26
:375
383,1984[Medline]
Schurek HJ, Jost U, Baumgartl H, Bertram H, Heckmann U: Evidence for a preglomerular oxygen diffusion shunt in rat renal cortex.
Am J Physiol259
:F910
F915,1990[Medline]
Fine LG, Bandyopadhay D, Norman JT: Is there a common mechanism for the progression of different types of renal diseases other than proteinuria? Towards the unifying theme of chronic hypoxia.
Kidney Int75
:S22
S26,2000
Kang DH, Kanellis J, Hugo C, Truong L, Anderson S, Kerjaschki D, Schreiner GF, Johnson RJ: Role of the microvascular endothelium in progressive renal disease.
J Am Soc Nephrol13
:806
816,2002[Abstract/Free Full Text]
Eckardt KU, Rosenberger C, Jurgensen JS, Wiesener MS: Role of hypoxia in the pathogenesis of renal disease.
Blood Purif21
:253
257,2003[CrossRef][Medline]
Nangaku M: Hypoxia and tubulointerstitial injury: A final common pathway to end-stage renal failure.
Nephron Exp Nephrol98
:e8
e12,2004[CrossRef][Medline]
Bohle A, von Gise H, Mackensen-Haen S, Stark-Jakob B: The obliteration of the postglomerular capillaries and its influence upon the function of both glomeruli and tubuli. Functional interpretation of morphologic findings.
Klin Wochenschr59
:1043
1051,1981[CrossRef][Medline]
Choi YJ, Chakraborty S, Nguyen V, Nguyen C, Kim BK, Shim SI, Suki WN, Truong LD: Peritubular capillary loss is associated with chronic tubulointerstitial injury in human kidney: Altered expression of vascular endothelial growth factor.
Hum Pathol31
:1491
1497,2000[CrossRef][Medline]
Yuan H-T, Li X-Z, Pitera JE, Long DA, Woolf AS: Peritubular capillary loss after mouse acute nephrotoxicity correlates with down-regulation of vascular endothelial growth factor-A and hypoxia-inducible factor-1alpha.
Am J Pathol163
:2289
2301,2003[Abstract/Free Full Text]
Kairaitis LK, Wang Y, Gassmann M, Tay YC, Harris DC: HIF-1alpha expression follows microvascular loss in advanced murine adriamycin nephrosis.
Am J Physiol Renal Physiol288
:F198
F206,2005[Abstract/Free Full Text]
Ohashi R, Kitamura H, Yamanaka N: Peritubular capillary injury during the progression of experimental glomerulonephritis in rats.
J Am Soc Nephrol11
:47
56,2000[Abstract/Free Full Text]
Norman JT, Orphanides C, Garcia P, Fine LG: Hypoxia-induced changes in extracellular matrix metabolism in renal cells.
Exp Nephrol7
:463
469,1999[CrossRef][Medline]
Norman JT, Clark IM, Garcia PL: Hypoxia promotes fibrogenesis in human renal fibroblasts.
Kidney Int58
:2351
2366,2000[CrossRef][Medline]
Tanaka T, Hanafusa N, Ingelfinger JR, Ohse T, Fujita T, Nangaku M: Hypoxia induces apoptosis in SV40-immortalized rat proximal tubular cells through the mitochondrial pathways, devoid of HIF-1-mediated upregulation of Bax.
Biochem Biophys Res Commun309
:222
231,2003[CrossRef][Medline]
Matsumoto M, Tanaka T, Yamamoto T, Noiri E, Miyata T, Inagi R, Fujita T, Nangaku M: Hypoperfusion of peritubular capillaries induced chronic hypoxia prior to progression of tubulointerstitial injury in a progressive model of rat glomerulonephritis.
J Am Soc Nephrol15
:1574
1581,2004[Abstract/Free Full Text]
Futrakul N, Tohsukhowong P, Patumraj S, Siriviriyakuk P, Tipprukmas N, Futrakul P: Treatments of hemodynamic maladjustment and oxidative stress prevent renal disease progression in chronically severe glomerulonephritides.
Ren Fail25
:839
844,2003[CrossRef][Medline]
Futrakul N, Vongthavarawat V, Sirisalipotch S, Chairatanarat T, Futrakul P, Suwanwalaikorn S: Tubular dysfunction and hemodynamic alteration in normoalbuminuric type 2 diabetes.
Clin Hemorheol Microcirc32
:59
65,2005[Medline]
Manotham K, Tanaka T, Matsumoto M, Ohse T, Miyata T, Inagi R, Kurokawa K, Fujita T, Nangaku M: Evidence of tubular hypoxia in the early phase in the remnant kidney model.
J Am Soc Nephrol15
:1277
1288,2004[Abstract/Free Full Text]
Lombardi D, Gordon KL, Polinsky P, Suga S, Schwartz SM, Johnson RJ: Salt-sensitive hypertension develops after short-term exposure to angiotensin II.
Hypertension33
:1013
1019,1999[Abstract/Free Full Text]
Shao J, Nangaku M, Miyata T, Inagi R, Yamada K, Kurokawa K, Fujita T: Imbalance of T-cell subsets in angiotensin II-infused hypertensive rats with kidney injury.
Hypertension42
:31
38,2003[Abstract/Free Full Text]
Astor BC, Muntner P, Levin A, Eustace JA, Coresh J: Association of kidney function with anemia: The Third National Health and Nutrition Examination Survey (19881994).
Arch Intern Med162
:1401
1408,2002[Abstract/Free Full Text]
NKF Kidney Early Evaluation Program: Anemia and chronic kidney disease.
Am J Kidney Dis45[Suppl 2]
:S71
S80,2005[CrossRef]
Iseki K, Ikemiya Y, Iseki C, Takishita S: Haematocrit and the risk of developing end-stage renal disease.
Nephrol Dial Transplant18
:899
905,2003[Abstract/Free Full Text]
Mohanram A, Zhang Z, Shahinfar S, Keane WF, Brenner BM, Toto RD: Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy.
Kidney Int66
:1131
1138,2004[CrossRef][Medline]
Adler S, Huang H: Impaired regulation of renal oxygen consumption in spontaneously hypertensive rats.
J Am Soc Nephrol13
:1788
1794,2002[Abstract/Free Full Text]
Welch WJ, Baumgartl H, Lubbers D, Wilcox CS: Nephron pO2 and renal oxygen usage in the hypertensive rat kidney.
Kidney Int59
:230
237,2001[Medline]
Palm F, Cederberg J, Hansell P, Liss P, Carlsson PO: Reactive oxygen species cause diabetes-induced decrease in renal oxygen tension.
Diabetologia46
:1153
1160,2003[CrossRef][Medline]
Welch WJ, Blau J, Xie H, Chabrashvili T, Wilcox CS: Angiotensin-induced defects in renal oxygenation: Role of oxidative stress.
Am J Physiol Heart Circ Physiol288
:H22
H28,2005[Abstract/Free Full Text]
Adler S, Huang H, Wolin MS, Kaminski PM: Oxidant stress leads to impaired regulation of renal cortical oxygen consumption by nitric oxide in the aging kidney.
J Am Soc Nephrol15
:52
60,2004[Abstract/Free Full Text]
Ries M, Basseau F, Tyndal B, Jones R, Deminiere C, Catargi B, Combe C, Moonen CW, Grenier N: Renal diffusion and BOLD MRI in experimental diabetic nephropathy. Blood oxygen level-dependent.
J Magn Reson Imaging17
:104
113,2003[CrossRef][Medline]
Tanaka T, Miyata T, Inagi R, Fujita T, Nangaku M: Hypoxia in renal disease with proteinuria and/or glomerular hypertension.
Am J Pathol165
:1979
1992,2004[Abstract/Free Full Text]
Ritz E: Starvation in the midst of plenty? The role of hypoxia in progression.
J Am Soc Nephrol16
:831
833,2005
Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC: Treating anemia early in renal failure patients slows the decline of renal function: A randomized controlled trial.
Kidney Int66
:753
760,2004[CrossRef][Medline]
Norman JT, Stidwill R, Singer M, Fine LG: Angiotensin II blockade augments renal cortical microvascular pO2 indicating a novel potential renoprotective action.
Nephron Physiol94
:39
46,2003
Welch WJ, Baumgartl H, Lubbers D, Wilcox CS: Renal oxygenation defects in the spontaneously hypertensive rat: Role of AT1 receptors.
Kidney Int63
:202
208,2003[CrossRef][Medline]
Eto N, Kojima I, Inagi R, Miyata T, Fujita T, Johnson RJ, Shankland SJ, Nangaku M: Protection of endothelial cells by dextran sulfate in rats of thrombotic microangiopathy.
J Am Soc Nephrol16
:2997
3005,2005[Abstract/Free Full Text]
Kang DH, Hughes J, Mazzali M, Schreiner GF, Johnson RJ: Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function.
J Am Soc Nephrol12
:1448
1457,2001[Abstract/Free Full Text]
Maxwell P: HIF-1: An oxygen response system with special relevance to the kidney.
J Am Soc Nephrol14
:2712
2722,2003[Free Full Text]
Marx J: Cell biology. How cells endure low oxygen.
Science303
:1454
1456,2004[Abstract/Free Full Text]
Semenza GL, Wang GL: A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation.
Mol Cell Biol12
:5447
5454,1992[Abstract/Free Full Text]
Wang GL, Semenza GL: General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia.
Proc Natl Acad Sci U S A90
:4304
4308,1993[Abstract/Free Full Text]
Epstein ACR, Gleadle JM, McNeill LA, Hewitson KS, ORourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian Y-M, Masson N, Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ, Ratcliffe PJ: C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation.
Cell107
:43
54,2001[CrossRef][Medline]
Manotham K, Tanaka T, Ohse T, Kojima I, Miyata T, Inagi R, Tanaka H, Sassa R, Fujita T, Nangaku M: A biological role of HIF-1 in the renal medulla.
Kidney Int67
:1428
1439,2005[CrossRef][Medline]
Elson DA, Thurston G, Huang LE, Ginzinger DG, McDonald DM, Johnson RS, Arbeit JM: Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1alpha.
Genes Dev15
:2520
2532,2001[Abstract/Free Full Text]
Freeburg PB, Abrahamson DR: Hypoxia-inducible factors and kidney vascular development.
J Am Soc Nephrol14
:2723
2730,2003[Abstract/Free Full Text]
Rosenberger C, Mandriota S, Jurgensen JS, Wiesener MS, Horstrup JH, Frei U, Ratcliffe PJ, Maxwell PH, Bachmann S, Eckardt K-U: Expression of hypoxia-inducible factor-1 and -2 in hypoxic and ischemic rat kidneys.
J Am Soc Nephrol13
:1721
1732,2002[Abstract/Free Full Text]
Wiesener MS, Jurgensen JS, Rosenberger C, Scholze CK, Horstrup JH, Warnecke C, Mandriota S, Bechmann I, Frei UA, Pugh CW, Ratcliffe PJ, Bachmann S, Maxwell PH, Eckardt KU: Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs.
FASEB J17
:271
273,2003[Abstract/Free Full Text]
Scortegagna M, Ding K, Zhang Q, Oktay Y, Bennett MJ, Bennett M, Shelton JM, Richardson JA, Moe O, Garcia JA: HIF-2alpha regulates murine hematopoietic development in an erythropoietin-dependent manner.
Blood105
:3133
3140,2005
Rosenberger C, Griethe W, Gruber G, Wiesener M, Frei U, Bachmann S, Eckardt KU: Cellular responses to hypoxia after renal segmental infarction.
Kidney Int64
:874
886,2003[CrossRef][Medline]
Rosenberger C, Heyman SN, Rosen S, Shina A, Goldfarb M, Griethe W, Frei U, Reinke P, Bachmann S, Eckardt KU: Up-regulation of HIF in experimental acute renal failure: Evidence for a protective transcriptional response to hypoxia.
Kidney Int67
:531
542,2005[CrossRef][Medline]
Tanaka T, Kojima I, Ohse T, Ingelfinger JR, Adler S, Fujita T, Nangaku M: Cobalt promotes angiogenesis via hypoxia-inducible factors and protects ischemic tubulointerstitium in the remnant kidney.
Lab Invest85
:1292
1307,2005[CrossRef][Medline]
Appelhoff RJ, Tian YM, Raval RR, Turley H, Harris AL, Pugh CW, Ratcliffe PJ, Gleadle JM: Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor.
J Biol Chem279
:38458
38465,2004[Abstract/Free Full Text]
Gardner HF: The use of cobaltous chloride in the anemia associated with chronic renal disease.
J Lab Clin Med41
:56
64,1953[Medline]
Matsumoto M, Makino Y, Tanaka T, Tanaka H, Ishizaka N, Noiri E, Fujita T, Nangaku M: Induction of renoprotective gene expression by cobalt ameliorates ischemic injury of the kidney in rats.
J Am Soc Nephrol14
:1825
1832,2003[Abstract/Free Full Text]
Tanaka T, Matsumoto M, Inagi R, Kojima I, Fujita T, Miyata T, Nangaku M: Induction of renoprotective gene expression by cobalt ameliorates tubulointerstitial injury in the progressive Thy1 nephritis model.
Kidney Int2005
, in press
Tanaka T, Kojima I, Ohse T, Inagi R, Miyata T, Ingelfinger JR, Fujita T, Nangaku M: Hypoxia-inducible factor (HIF) modulates tubular cell survival in cisplatin nephrotoxicity.
Am J Physiol Renal Physiol289
:F1123
F1133,2005[Abstract/Free Full Text]
Warnecke C, Griethe W, Weidemann A, Jurgensen JS, Willam C, Bachmann S, Ivashchenko Y, Wagner I, Frei U, Wiesener M, Eckardt KU: Activation of the hypoxia-inducible factor-pathway and stimulation of angiogenesis by application of prolyl hydroxylase inhibitors.
FASEB J17
:1186
1188,2003[Abstract/Free Full Text]
This article has been cited by other articles:
A. M. Luks, R. J. Johnson, and E. R. Swenson Chronic Kidney Disease at High Altitude
J. Am. Soc. Nephrol.,
December 1, 2008;
19(12):
2262 - 2271.
[Abstract][Full Text][PDF]
R. Shibata, S. Ueda, S.-i. Yamagishi, Y. Kaida, Y. Matsumoto, K. Fukami, A. Hayashida, H. Matsuoka, S. Kato, M. Kimoto, et al. Involvement of asymmetric dimethylarginine (ADMA) in tubulointerstitial ischaemia in the early phase of diabetic nephropathy
Nephrol. Dial. Transplant.,
November 17, 2008;
(2008)
gfn630v1.
[Abstract][Full Text][PDF]
S. Lee, W. Kim, D. H. Kim, S.-O. Moon, Y. J. Jung, A. S. Lee, K. P. Kang, K. Y. Jang, S. Y. Lee, M. J. Sung, et al. Protective effect of COMP-angiopoietin-1 on cyclosporine-induced renal injury in mice
Nephrol. Dial. Transplant.,
September 1, 2008;
23(9):
2784 - 2794.
[Abstract][Full Text][PDF]
M. M. Yeboah, X. Xue, M. Javdan, M. Susin, and C. N. Metz Nicotinic acetylcholine receptor expression and regulation in the rat kidney after ischemia-reperfusion injury
Am J Physiol Renal Physiol,
September 1, 2008;
295(3):
F654 - F661.
[Abstract][Full Text][PDF]
B. I. Levy, E. L. Schiffrin, J.-J. Mourad, D. Agostini, E. Vicaut, M. E. Safar, and H. A.J. Struijker-Boudier Impaired Tissue Perfusion: A Pathology Common to Hypertension, Obesity, and Diabetes Mellitus
Circulation,
August 26, 2008;
118(9):
968 - 976.
[Full Text][PDF]
H. Kimura, X. Li, K. Torii, T. Okada, N. Takahashi, H. Fujii, S. Ishihara, and H. Yoshida A natural PPAR-{gamma} agonist, 15-deoxy-delta 12,14-prostaglandin J2, may act as an enhancer of PAI-1 in human proximal renal tubular cells under hypoxic and inflammatory conditions
Nephrol. Dial. Transplant.,
August 1, 2008;
23(8):
2496 - 2503.
[Abstract][Full Text][PDF]
H. Nishi, R. Inagi, H. Kato, M. Tanemoto, I. Kojima, D. Son, T. Fujita, and M. Nangaku Hemoglobin Is Expressed by Mesangial Cells and Reduces Oxidant Stress
J. Am. Soc. Nephrol.,
August 1, 2008;
19(8):
1500 - 1508.
[Abstract][Full Text][PDF]
D. Chhabra, M. Grafals, A. I. Skaro, M. Parker, and L. Gallon Impact of Anemia after Renal Transplantation on Patient and Graft Survival and on Rate of Acute Rejection
Clin. J. Am. Soc. Nephrol.,
July 1, 2008;
3(4):
1168 - 1174.
[Abstract][Full Text][PDF]
H. Kitamura, Y. Isaka, Y. Takabatake, R. Imamura, C. Suzuki, S. Takahara, and E. Imai Nonerythropoietic derivative of erythropoietin protects against tubulointerstitial injury in a unilateral ureteral obstruction model
Nephrol. Dial. Transplant.,
May 1, 2008;
23(5):
1521 - 1528.
[Abstract][Full Text][PDF]
S. Ohtomo, M. Nangaku, Y. Izuhara, S. Takizawa, C. v. Y. d. Strihou, and T. Miyata Cobalt ameliorates renal injury in an obese, hypertensive type 2 diabetes rat model
Nephrol. Dial. Transplant.,
April 1, 2008;
23(4):
1166 - 1172.
[Abstract][Full Text][PDF]
G. J. Ko, C.-S. Boo, S.-K. Jo, W. Y. Cho, and H. K. Kim Macrophages contribute to the development of renal fibrosis following ischaemia/reperfusion-induced acute kidney injury
Nephrol. Dial. Transplant.,
March 1, 2008;
23(3):
842 - 852.
[Abstract][Full Text][PDF]